
    
      This is a multicenter, open-label, uncontrolled, repeat-dose Phase 1/2a study designed to
      evaluate the safety profile and to determine the recommended Phase 2 dose of GNS561 in
      patients with advanced primary and secondary liver cancer. This study will enroll
      approximately 50 patients and consists of 2 parts: Phase 1(dose escalation) and Phase 2
      (expansion). All patients will be treated until the occurrence of an unacceptable toxicity,
      disease progression, or withdrawal of consent. In this study a treatment cycle is defined as
      4 weeks (28 days). Patients are to take their assigned dose of GNS561, in the Morning and in
      the evening at the same time everyday, following a meal.
    
  